HC Wainwright & Co. Reiterates Buy on Denali Therapeutics, Maintains $105 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Andrew Fein reiterated a Buy rating on Denali Therapeutics (NASDAQ:DNLI) and maintained a $105 price target.
June 21, 2023 | 10:24 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Andrew Fein reiterated a Buy rating on Denali Therapeutics and maintained a $105 price target.
The reiteration of a Buy rating and maintenance of a $105 price target by HC Wainwright & Co. analyst Andrew Fein indicates a positive outlook for Denali Therapeutics. This news is likely to have a positive short-term impact on DNLI's stock price as it shows confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100